数千万Pre-A轮融资！泛血管与生命循环支持创新企业

Core Viewpoint - The article highlights the recent completion of a multi-million yuan Pre-A round financing by Maikesi Medical Technology, aimed at advancing product development and clinical registration in the vascular emergency and life support sector, thereby strengthening its leading position in domestic production [2]. Industry Background - The incidence of critical conditions such as cardiogenic shock and aortic hemorrhage is on the rise, with emergency and circulatory support equipment heavily reliant on imports. The aging population and increasing burden of cardiovascular diseases necessitate effective restoration of circulatory function within the "golden rescue time" [3]. - Internationally, life support equipment represented by VAD and REBOA is gaining attention in critical care and pre-hospital emergency fields. However, existing imported products face issues like high costs and significant risks, making domestic alternatives essential for industry upgrades [3]. Company Introduction - Established in 2023 and headquartered in Shaoxing, Maikesi Medical is one of the few companies in China focusing on the entire chain of "intervention + emergency + service" for life support devices. The core team comprises experts from cardiovascular intervention, mechanical design, and emergency medicine [6]. - Since its inception, the company has aimed to develop a comprehensive technology and service system, focusing on high-risk PCI, cardiogenic shock, trauma, and pre-hospital emergency scenarios, with a product pipeline that combines proprietary intellectual property and mass production capabilities [6]. Product Introduction - Maikesi Medical has developed three core products: 1. PulseVAD®: A catheter-based artificial heart system with a diameter of less than 14Fr, reducing vascular damage and limb ischemia risks. It operates in a bionic pulsatile mode, providing effective blood flow support [9]. 2. Mcsreboa®: A resuscitative aortic occlusion balloon that integrates ultrasound guidance and automatic inflation technology, enhancing success rates in emergency situations [10]. 3. Smartpress™: An intelligent CPR device that ensures stable and precise chest compressions, improving resuscitation quality and neurological recovery rates [11]. - This product combination creates a complete closed-loop from intervention support to emergency resuscitation, addressing critical treatment scenarios [11]. Financing Purpose - The recent financing will focus on: - Advancing clinical registration and certification for core products - Establishing high-standard production lines and quality systems - Strengthening market education and clinical training systems - Promoting collaboration between pre-hospital emergency, intensive care, and intervention centers [12]. - The company plans to complete core product registrations and achieve mass production within two years, while also initiating overseas registration and collaboration processes to build an internationally competitive life support technology platform [12].